ID | 32998 |
フルテキストURL | |
著者 |
Koizumi, Hiroki
Department of Psychiatry, Chiba University Graduate School of Medicine
Hashimoto, Kenji
Department of Psychiatry, Chiba University Graduate School of Medicine
Kumakiri, Chikara
Department of Psychiatry, Chiba University Graduate School of Medicine
Shimizu, Eiji
Department of Psychiatry, Chiba University Graduate School of Medicine
Sekine, Yoshimoto
Department of Psychiatry and Neurology, Hamamatsu University School of Medicine
Ozaki, Norio
Department of Psychiatry, Fujita Health University School of Medicine
Inada, Toshiya
Department of Psychiatry, Nagoya University Graduate School of Medicine
Harano, Mutsuo
Department of Neuropsychiatry, Kurume University School of Medicine
Komiyama, Tokutaro
National Center Hospital for Mental, Nervous, and Muscular Disorders, National Center of Neurology and Psychiatry
Yamada, Mitsuhiko
Karasuyama Hospital, Showa University School of Medicine
Sora, Ichiro
Division of Psychobiology, Tohoku University Graduate School of Medicine
Ujike, Hiroshi
Department of Neuropsychiatry, Okayama University Graduate School of Medicine and Dentistry
Takei, Nori
Department of Psychiatry and Neurology, Hamamatsu University School of Medicine
Iyo, Masaomi
Department of Psychiatry, Chiba University Graduate School of Medicine
|
抄録 | Several lines of evidence suggest that increased generation of auto-oxidized dopamine (DA) o-quinone is associated with the neurotoxicity of methamphetamine (MAP) in the brain, and that, as a cellular defenses against DA-derived quinines, glutathione S-transferase (GST) detoxifies auto-oxidized DA o-quinone in the brain. Glutathione S-transferase M1 (GSTM1) of the mu-class of GSTs catalyzes reaction between glutathione and catecholamine o-quinones under physiological conditions. This study was undertaken to investigate the role of the GSTM1 gene deletion polymorphism in the neuropathology of MAP abuse. One hundred fifty-seven MAP abusers and 200 healthy comparison subjects were tested for a genetic polymorphism of GSTM1. The difference in the frequency of deletion (D)/nondeletion (N) alleles between the female abusers and female controls was close to statistical significance (P=0.071), although there was no statistical difference (P=0.651) between male abusers and male controls. Furthermore, the number of female abusers with deletion alleles was significantly (P=0.007, odds ratio: 2.77, 95% CI 1.30-5.89) higher than that of male abusers with deletion alleles. These findings suggest that GSTM1 gene deletion may contribute to a vulnerability to MAP abuse in female subjects, but not in male subjects. (C) 2003 Wiley-Liss, Inc.
|
キーワード | methamphetamine
drug abuse
Glutathione S-transferase
gender difference
|
備考 | Digital Object Identifer:10.1002/ajmg.b.20148
Published with permission from the copyright holder. This is the author's copy, as published in American Journal of Medical Genetics Part B, Neuropsychiatric Genetics, Apr 2004, Volume 126B, Issue 1, Pages 43-45. Publisher URL:http://dx.doi.org/10.1002/ajmg.b.20148 Direct access to Thomson Web of Science record Copyright © 2003 Wiley-Liss, Inc. All rights reserved. |
発行日 | 2004-04-01
|
出版物タイトル |
American Journal of Medical Genetics Part B, Neuropsychiatric Genetics
|
巻 | 126B巻
|
号 | 1号
|
出版者 | Wiley-Liss, Inc.
|
開始ページ | 43
|
終了ページ | 45
|
ISSN | 0148-7299
|
NCID | AA11815089
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
著作権者 | Wiley-Liss, Inc.
|
論文のバージョン | author
|
査読 |
有り
|
DOI | |
PubMed ID | |
Web of Science KeyUT | |
Submission Path | biology_general/31
|